Programme
Monday 24 January
Chairs: Chris Holcombe & Sarah Vinnicombe
Minimally invasive techniques for therapeutic treatment of cancers
Risk-adapted tailored breast radiotherapy: one size no longer fits all
Risk-adapted axillary surgery including TAD and its practical aspects
What's new in DCIS: A grand challenge
Panel discussion
Chairs: Judith Bliss & Mairead Mackenzie
Pre-surgical provocation tests for clinical trials and management
Are CDK 4/6 inhibitors ready for clinical use?
Optimising systemic therapy for women with BRCA mutations: Current knowledge and future directions
Neoadjuvant anti-HER2 therapy enabled risk adaptation: An era to optimise practice
Panel discussion
Chairs: Sarah Pinder & Gareth Evans
Molecular evolution of breast cancer
Personalised breast cancer screening
Past, present and future directions in breast cancer genetics
Strategies to prevent breast cancer
Panel discussion
Chairs: Caroline Wilson and Leena Chagla
Should we be offering next generation sequencing for routine clinical use?
Immunotherapy for metastatic breast cancer
Optimal management and treatment sequencing of ER+ HER2- metastatic breast cancer
Role of surgery in metastatic breast cancer
Panel discussion
Promotional industry-led symposium organised and funded by Gilead Sciences Ltd.
Tuesday 25 January
Chairs: Professor Stephen Johnston
Chairs: Ingunn Holen and Thomas Hughes
Co-targeting CDK4/6 and AKT with endocrine therapy overcomes CDK4/6 inhibitor and endocrine therapy resistance in preclinical breast cancer models
The challenge of modelling of brain metastases - combining in vivo, cell culture and organotypic approaches to investigate brain extravasation
The role of gamma delta T cells in breast cancer development/metastasis
Understanding breast cancer through use of single-cell systems biology
Chairs: Anne Armstrong and Lesley Turner
Unmet need and follow-up
Breast Cancer Now's Helpline and patient focused resources
Identifying theory and evidence-based psychosocial factors associated with adherence to adjuvant hormonal therapy: understanding individual differences to tailor interventions
Supporting women with adherence to endocrine therapy following breast cancer: the SWEET programme
Chairs: Baroness Delyth Morgan and Catherine Harper-Wynne
Future of cancer services in the UK
Future vision for breast surgery
Future vision for radiotherapy
Future vision for pathology
Future vision for radiology
Future vision for clinical trials
Future vision for systemic therapies
Panel discussion
Chairs: Mark Verrill
Welcome and Introduction
Summary of the RxPONDER publication
